Loading...
Loading...
PRFX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 6.0K |
| Gross Profit | -6.0K |
| Operating Expense | 3,558.0K |
| Operating I/L | -3,564.0K |
| Other Income/Expense | -1,319.0K |
| Interest Income | 101.0K |
| Pretax | -4,883.0K |
| Income Tax Expense | 8.0K |
| Net Income/Loss | -4,891.0K |
PainReform Ltd. is a clinical stage specialty pharmaceutical company based in Israel. The company is focused on developing PRF-110, a clear oil-based solution that provides extended post-surgical pain relief by being directly instilled into the surgical wound. This product is currently undergoing two Phase 3 clinical trials for patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. generates revenue through the development and potential commercialization of PRF-110, offering a unique approach to localized and extended post-operative analgesia.
